NASDAQ:ONS - Oncobiologics Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Oncobiologics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.04 -0.04 (-3.70 %) (As of 01/27/2020 07:11 AM ET) Add Compare Today's Range$1.00Now: $1.04▼$1.1150-Day Range$0.72MA: $2.15▼$7.4052-Week Range$0.57Now: $1.04▼$1.53Volume545,945 shsAverage Volume69,024 shsMarket Capitalization$75.09 millionP/E RatioN/ADividend YieldN/ABeta-0.27 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Oncobiologics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics in immunology and oncology disease areas. Its advanced product candidate is ONS-3010, an adalimumab biosimilar that is in a Phase 1 clinical trial, which targets the tumor necrosis factor alpha. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONS Previous SymbolNYSE:ONS CUSIPN/A CIK1649989 Webhttp://www.oncobiologics.com/ Phone609-619-3990Debt Debt-to-Equity RatioN/A Current Ratio0.41 Quick Ratio0.41Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.81 million Price / Sales19.71 Cash FlowN/A Price / Cash FlowN/A Book Value($1.36) per share Price / Book-0.76Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-38,840,000.00 Net Margins-464.47% Return on EquityN/A Return on Assets-93.28%Miscellaneous EmployeesN/A Outstanding Shares72,200,000Market Cap$75.09 million Next Earnings DateN/A OptionableNot Optionable Receive ONS News and Ratings via Email Sign-up to receive the latest news and ratings for ONS and its competitors with MarketBeat's FREE daily newsletter. Oncobiologics (NASDAQ:ONS) Frequently Asked Questions What is Oncobiologics' stock symbol? Oncobiologics trades on the NASDAQ under the ticker symbol "ONS." Has Oncobiologics been receiving favorable news coverage? News headlines about ONS stock have been trending somewhat negative this week, InfoTrie reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Oncobiologics earned a news impact score of -1.4 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Oncobiologics. Who are some of Oncobiologics' key competitors? Some companies that are related to Oncobiologics include Replimune Group (REPL), Agenus (AGEN), Precision BioSciences (DTIL), Translate Bio (TBIO), Verona Pharma (TARA), Voyager Therapeutics (VYGR), Aptose Biosciences (APTO), BioCryst Pharmaceuticals (BCRX), Cabaletta Bio (CABA), Adaptimmune Therapeutics (ADAP), Autolus Therapeutics (AUTL), Harpoon Therapeutics (HARP), PDL BioPharma (PDLI), Tcr2 Therapeutics (TCRR) and Compugen (CGEN). What other stocks do shareholders of Oncobiologics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oncobiologics investors own include Crispr Therapeutics (CRSP), Network-1 Technologies (NTIP), Allena Pharmaceuticals (ALNA), Intra-Cellular Therapies (ITCI), Cidara Therapeutics (CDTX), Neuralstem (CUR), Exelixis (EXEL), Fate Therapeutics (FATE), Ardelyx (ARDX) and Atara Biotherapeutics (ATRA). Who are Oncobiologics' key executives? Oncobiologics' management team includes the folowing people: Mr. Lawrence A. Kenyon, Pres, CEO, CFO, Principal Accounting Officer, Company Sec.,Treasurer & Director (Age 52)Dr. Pankaj Mohan, Founder & Director (Age 53)Dr. Kenneth M. Bahrt, Chief Medical Officer (Age 65)Mr. Ralph H. Thurman, Exec. Chairman (Age 69)Rick Gregory, Director of Marketing & Communications When did Oncobiologics IPO? (ONS) raised $35 million in an initial public offering on Friday, May 13th 2016. The company issued 5,800,000 shares at $6.00 per share. Jefferies and Barclays acted as the underwriters for the IPO and Cantor Fitzgerald & Co. was co-manager. What is Oncobiologics' stock price today? One share of ONS stock can currently be purchased for approximately $1.04. How big of a company is Oncobiologics? Oncobiologics has a market capitalization of $75.09 million and generates $3.81 million in revenue each year. View Additional Information About Oncobiologics. What is Oncobiologics' official website? The official website for Oncobiologics is http://www.oncobiologics.com/. How can I contact Oncobiologics? Oncobiologics' mailing address is 7 CLARKE DRIVE, CRANBURY NJ, 08512. The company can be reached via phone at 609-619-3990 or via email at [email protected] MarketBeat Community Rating for Oncobiologics (NASDAQ ONS)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 173 (Vote Outperform)Underperform Votes: 198 (Vote Underperform)Total Votes: 371MarketBeat's community ratings are surveys of what our community members think about Oncobiologics and other stocks. Vote "Outperform" if you believe ONS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/27/2020 by MarketBeat.com StaffFeatured Article: Why do earnings reports matter?
